154 related articles for article (PubMed ID: 16906374)
21. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
22. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
23. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus.
Liossis SN; Solomou EE; Dimopoulos MA; Panayiotidis P; Mavrikakis MM; Sfikakis PP
J Investig Med; 2001 Mar; 49(2):157-65. PubMed ID: 11288756
[TBL] [Abstract][Full Text] [Related]
24. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus.
Cheng Y; Yan S; Zhao W; Huang Q; Lian L; Wei W
Scand J Clin Lab Invest; 2013 Mar; 73(2):141-7. PubMed ID: 23336587
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
26. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
27. CD22 and autoimmune disease.
Dörner T; Shock A; Smith KG
Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
[TBL] [Abstract][Full Text] [Related]
28. Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.
Yoshikawa M; Nakayamada S; Kubo S; Nawata A; Kitanaga Y; Iwata S; Sakata K; Ma X; Wang SP; Nakano K; Saito K; Tanaka Y
Clin Immunol; 2019 Mar; 200():1-9. PubMed ID: 30576845
[TBL] [Abstract][Full Text] [Related]
29. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
30. Increased interleukin 21 and follicular helper T-like cells and reduced interleukin 10+ B cells in patients with new-onset systemic lupus erythematosus.
Wang L; Zhao P; Ma L; Shan Y; Jiang Z; Wang J; Jiang Y
J Rheumatol; 2014 Sep; 41(9):1781-92. PubMed ID: 25028374
[TBL] [Abstract][Full Text] [Related]
31. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
[TBL] [Abstract][Full Text] [Related]
32. Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MH; Carrasco S; Goldenstein-Schainberg C
J Rheumatol; 2007 Jul; 34(7):1580-4. PubMed ID: 17516614
[TBL] [Abstract][Full Text] [Related]
33. CD19
Xiong H; Tang Z; Xu Y; Shi Z; Guo Z; Liu X; Tan G; Ai X; Guo Q
Adv Rheumatol; 2022 Dec; 62(1):48. PubMed ID: 36494762
[TBL] [Abstract][Full Text] [Related]
34. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression.
Korganow AS; Knapp AM; Nehme-Schuster H; Soulas-Sprauel P; Poindron V; Pasquali JL; Martin T
J Autoimmun; 2010 Jun; 34(4):426-34. PubMed ID: 19963348
[TBL] [Abstract][Full Text] [Related]
35. The Expansion of CD25 high IL-10 high FoxP3 high B Regulatory Cells Is in Association with SLE Disease Activity.
Vadasz Z; Peri R; Eiza N; Slobodin G; Balbir-Gurman A; Toubi E
J Immunol Res; 2015; 2015():254245. PubMed ID: 26504851
[TBL] [Abstract][Full Text] [Related]
36. B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity.
Fujimoto M; Sato S
J Dermatol Sci; 2007 Apr; 46(1):1-9. PubMed ID: 17223015
[TBL] [Abstract][Full Text] [Related]
37. Characterization of 5C11-positive activated interferon-producing cells in patients with systemic lupus erythematosus.
Ohshima M; Kanda H; Kubo K; Yonezumi-Hayashi A; Tateishi S; Yamamoto K
Lupus; 2013 Jan; 22(1):44-51. PubMed ID: 23087259
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD22 on peripheral B cells in patients with rheumatoid arthritis: relation to CD5-positive B cells.
Nakiri Y; Minowa K; Suzuki J; Mitsuo A; Amano H; Morimoto S; Tokano Y; Takasaki Y
Clin Rheumatol; 2007 Oct; 26(10):1721-3. PubMed ID: 17585360
[TBL] [Abstract][Full Text] [Related]
39. Two systemic lupus erythematosus (SLE) global disease activity indexes--the SLE Disease Activity Index and the Systemic Lupus Activity Measure--demonstrate different correlations with activation of peripheral blood CD4+ T cells.
Daca A; Czuszyńska Z; Smoleńska Z; Zdrojewski Z; Witkowski JM; Bryl E
Hum Immunol; 2011 Dec; 72(12):1160-7. PubMed ID: 21906646
[TBL] [Abstract][Full Text] [Related]
40. Abnormal telomerase activity and telomere length in T and B cells from patients with systemic lupus erythematosus.
Kurosaka D; Yasuda J; Yoshida K; Yoneda A; Yasuda C; Kingetsu I; Toyokawa Y; Yokoyama T; Saito S; Yamada A
J Rheumatol; 2006 Jun; 33(6):1102-7. PubMed ID: 16755657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
